BP
AMED

Ballentine Partners’s Amedisys AMED Stock Holding History

Ballentine Partners’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,844
Closed -$772K – 1020
2025
Q2 		$772K Buy
7,844
+3,816
+95% +$361K 0.01% 369
2025
Q1 		$373K Buy
4,028
+344
+9% +$31.7K 0.01% 544
2024
Q4 		$334K Buy
+3,684
New +$338K 0.01% 561

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ballentine Partners's AMED Position: Q3 2025 in Review

Ballentine Partners sold out of Amedisys (AMED) in Q3 2025, closing a stake of 7,844 shares — an estimated $772K sold.

Ballentine Partners first reported a position in AMED in Q4 2024 and held it in 3 quarters. The position peaked at $772K in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Ballentine Partners reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Ballentine Partners sold 7,844 Amedisys shares in Q3 2025, an estimated $772K.
  • Ballentine Partners first reported a position in Amedisys in Q4 2024 and held it in 3 quarters.
  • Ballentine Partners's Amedisys position peaked at $772K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Ballentine Partners's 13F filing for Q3 2025, filed 3 Nov 2025.